4D Molecular Therapeutics

FDMT · NASDAQ

$13.10+$0.81 (+6.59%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $12.29

Latest news

NewsOct 20, 8:06 AM ETAvi Kapoor
General Motors, Genuine Parts, Steel Dynamics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Press releaseOct 16, 4:05 PM ETGlobe Newswire
4DMT Announces New Employment Inducement Grants
Press releaseOct 5, 8:00 AM ETGlobe Newswire
4DMT to Host Investor Day on October 21, 2026
Press releaseSep 28, 8:00 AM ETGlobe Newswire
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
NewsSep 25, 8:03 AM ETAvi Kapoor
Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
Press releaseSep 11, 4:05 PM ETGlobe Newswire
4DMT Announces New Employment Inducement Grants
Press releaseAug 25, 8:00 AM ETGlobe Newswire
4DMT to Participate in Upcoming Investor Conferences
Press releaseAug 14, 4:05 PM ETGlobe Newswire
4DMT Announces New Employment Inducement Grants
Press releaseAug 13, 4:05 PM ETGlobe Newswire
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
NewsJul 20, 9:05 AM ETVandana Singh
4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win
Press releaseJul 18, 3:15 PM ETGlobe Newswire
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
Press releaseJul 17, 4:05 PM ETGlobe Newswire
4DMT Announces New Employment Inducement Grants
Press releaseJun 30, 4:05 PM ETGlobe Newswire
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
NewsMar 18, 4:34 PM ET
UPDATE: 4D Molecular Therapeutics Q4 EPS $0.43 Beats $(0.53) Estimate, Sales $85.090M Beat $32.245M Estimate
NewsJan 28, 9:01 AM ET
Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings)
NewsDec 19, 8:05 AM ETAvi Kapoor
BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
NewsNov 6, 7:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsOct 21, 5:00 PM ET
Beyond The Numbers: 4 Analysts Discuss 4D Molecular Therapeutics Stock
NewsOct 8, 1:35 PM ET
10 Health Care Stocks Whale Activity In Today's Session
NewsSep 3, 7:46 AM ETAvi Kapoor
Jim Cramer: AppLovin Calls For Prudence, This Health Care Stock Is 'Pure Spec'
NewsAug 12, 3:01 PM ET
What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics
NewsAug 4, 1:06 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsAug 1, 6:04 PM ET
Assessing 4D Molecular Therapeutics: Insights From 5 Financial Analysts
NewsAug 1, 8:07 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsAug 1, 7:15 AM ET
Market-Moving News for August 1st
NewsAug 1, 6:56 AM ETAvi Kapoor
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
NewsJul 31, 5:07 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseJul 31, 4:05 PM ETGlobe Newswire
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
NewsJul 3, 3:01 PM ET
What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics
NewsMar 3, 9:01 AM ET
Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics
Press releaseFeb 11, 4:43 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
NewsFeb 10, 10:26 AM ETVandana Singh
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study
NewsFeb 10, 7:00 AM ET
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts
Press releaseFeb 4, 3:55 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
Press releaseJan 28, 12:00 PM ETPRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
Press releaseJan 21, 6:10 PM ETPRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
NewsJan 13, 8:00 AM ET
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts
NewsDec 18, 5:00 PM ET
What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics
NewsNov 14, 12:00 PM ET
Analyst Expectations For 4D Molecular Therapeutics's Future
NewsSep 19, 2:34 PM ETVandana Singh
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate
Press releaseSep 17, 8:00 AM ETBusiness Wire
Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm
Press releaseSep 12, 5:49 PM ETBusiness Wire
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
NewsSep 9, 2:01 PM ET
The Latest Analyst Ratings For 4D Molecular Therapeutics
Press releaseAug 26, 7:40 PM ETPRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
Press releaseAug 17, 10:00 PM ETPRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

General Motors, Genuine Parts, Steel Dynamics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

4DMT Announces New Employment Inducement Grants

4DMT to Host Investor Day on October 21, 2026

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

4DMT Announces New Employment Inducement Grants

4DMT to Participate in Upcoming Investor Conferences

4DMT Announces New Employment Inducement Grants

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

4DMT Announces New Employment Inducement Grants

4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists

UPDATE: 4D Molecular Therapeutics Q4 EPS $0.43 Beats $(0.53) Estimate, Sales $85.090M Beat $32.245M Estimate

Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings)

BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Beyond The Numbers: 4 Analysts Discuss 4D Molecular Therapeutics Stock

10 Health Care Stocks Whale Activity In Today's Session

Jim Cramer: AppLovin Calls For Prudence, This Health Care Stock Is 'Pure Spec'

What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics

12 Health Care Stocks Moving In Monday's Intraday Session

Assessing 4D Molecular Therapeutics: Insights From 5 Financial Analysts

12 Health Care Stocks Moving In Friday's Pre-Market Session

Market-Moving News for August 1st

Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Thursday's After-Market Session

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics

Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study

A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts

What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics

Analyst Expectations For 4D Molecular Therapeutics's Future

4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate

Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm

FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

The Latest Analyst Ratings For 4D Molecular Therapeutics

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT